(1600 or 800 mg 2 times a day for 3 days) or trimethoprim (200 mg 2 times a day for 5 days) can be administered only in regions where the resistance of E. coli to them is ≤ 20%. Spasmolytics are also prescribed in severe pain syndrome.

Prevention of acute cystitis includes phytopreparations with diuretic effect: lingonberries, cranberries, etc.

**Conclusions.** In the study of treatment protocols acute cystitis was concluded that the main treatment regimen assignment will be antibacterially therapy.

---

**PHARMACOLOGICAL GROUNDING FOR THE USE OF IVERMECTIN IN THE TREATMENT OF COVID-19**

Purykina N. Y.

Scientific supervisor: Sakharova T. S.

National University of Pharmacy, Kharkiv, Ukraine

northnonna@gmail.com

**Introduction.** In today's coronavirus pandemic, particularly interesting is the antiparasitic agent Ivermectin, which has shown significant antiviral activity against the SARS-CoV-2 virus in vitro. After a single addition of Ivermectin to infected culture cells, the drug showed a nearly 5000-fold reduction in viral RNA within 48 hours. Based on these data, a number of studies have been carried out which showed the antiviral activity of Ivermectin for the mono- and combination therapy.

**Aim.** Analysis of the status regarding the efficacy and safety of the drug Ivermectin for the prophylaxis and mono- or combination therapy of COVID-19.

**Materials and Methods.** Information research and processing of current literature on the pharmacological characteristics and clinical application of the drug Ivermectin from the group of antiparasitic drugs avermectins.

**Results and discussion.** In October 2020, the FLCCC Alliance developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. It’s centered around Ivermectin which is one of the safest drugs known. Current research and clinical trials are ongoing on this topic.

Scientists at Benha University in Egypt randomized 200 health care and households contacts of COVID-19 patients. They reported a large and statistically significant reduction in contacts testing positive by RT PCR when treated with Ivermectin vs. controls, 2% vs 10%.

In a study of Chinese and Bangladesh scientists, there were two groups tested positive for SARS-CoV-2 infection. Group A (n=60) was given Ivermectin in combination with Doxycycline, while Group B (n=56) received Hydroxychloroquine in combination with Azithromycin. In a Chinese study of the efficacy of Ivermectin in combination with Doxycycline, the mean time to symptom recovery was 5.93 days (5 to 10 days) in group A and 6.99 days (4 to 12 days) in group B. Ivermectin was not associated with any serious side-effects in all the trials, the main one being headache, and the overall tolerability was good.

**Conclusion.** The results in each of researches showed the moderate effectiveness in prophylaxis and mono- or combination therapy of COVID-19, which opens up the perspective of using Ivermectin as an anticovid drug and grounds a further search for drugs of similar action among its analogues.